(Reuters) - Its comment came after Sanofi and its U.S. partner Bristol-Myers Squibb on Tuesday won a U.S. trial upholding a patent on Sanofi's blockbuster bloodthinner Plavix.
"Our position on Sanofi has not changed since our annual general meeting last month," a spokeswoman at Total said, giving no further details on the timing of a sale.
Read more at Reuters.com Mergers News
"Our position on Sanofi has not changed since our annual general meeting last month," a spokeswoman at Total said, giving no further details on the timing of a sale.
Read more at Reuters.com Mergers News
No comments:
Post a Comment